Pfizer Selzentry Will Launch At $29/Day; sNDA For Full Approval Slated For August

Pfizer's HIV therapy Selzentry (maraviroc) will be available in pharmacies by mid-September following FDA's Aug. 6 approval of the first-in-class CCR5 co-receptor antagonist